AVACTA GROUP PLC (AVCT) — Review of the AVA6000 clinical trial’s Phase 1a data

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the AVACTA Investor Presentation relating to the review of the AVA6000 Clinical Trials Phase one data. Throughout this recorded presentation, investors will be in listen only mode. Given the significant attendance today with over 1,600 shareholders and investors attending today's call, the company will not be able to answer all questions submitted during the meeting itself. We have received a significant number of pre submitted questions, and the company have reviewed those questions and we'll categorize some responses to those sectors in the Q and A session at the end. Questions can be still submitted using the Q and A tab situated on the right hand corner of your screen. Just simply type in your question at any time and press send. The company can review these post today's meeting as well. Before we begin, we'd like to submit the following poll. I'm sure the company will be most grateful for your participation. And I'd now like to hand over to CEO, Alastair Smith. Good morning. Good morning, Mark. Thanks very much indeed, and welcome, everybody, and thank you for sparing some time today. So this morning, we're going to be presenting a summary of key data from the development of AVACTA both preclinical and clinical data. And I'm joined by Doctor Fiona McLaughlin, Chief Scientific Officer, and Doctor Chris Cocklin, Oncologist, Immunologist and Consultant to the company. So before we get, into the presentation of the data, I just want to set the scene. The overarching takeaway message from the data that we're going to present to you is that precision works as it was designed to do. And what do we mean by it works? Well, we're going to show you data that shows us that a precision chemotherapy cannot get into cells so i...